Rapid Communication
Pulmonary Alveolar Proteinosis Is a Disease of Decreased Availability of GM-CSF Rather than an Intrinsic Cellular Defect

https://doi.org/10.1006/clim.2000.4859Get rights and content

Abstract

Granulocyte–macrophage colony stimulating factor (GM-CSF) deficient mice develop a pulmonary alveolar proteinosis (PAP) syndrome which is corrected by the administration/expression of GM-CSF. These observations implicate GM-CSF in the pathogenesis of human PAP. We hypothesized that human PAP may involve an intrinsic cellular defect in monocytes/macrophages with an inability to produce GM-CSF and/or respond to GM-CSF. Thus, we investigated the cytokine responses to GM-CSF and LPS from peripheral blood monocytes and alveolar macrophages from patients with idiopathic PAP and healthy controls. Macrophage inflammatory protein-1-α (MIP) was measured from GM-CSF-stimulated cells and GM-CSF was measured from LPS-stimulated cells by ELISA. The MIP and GM-CSF production by monocytes and alveolar macrophages did not differ between PAP patients and healthy controls. Growth of the GM-CSF-dependent human myeloid cell line TF-1 was inhibited by serum from all patients studied (n = 10) and all patients had anti-GM-CSF antibody in their serum. The BAL from PAP patients had less detectable GM-CSF by ELISA than healthy controls (P = 0.05); in contrast, the inhibitory cytokine, interleukin-10 (IL-10), was increased in PAP compared to controls (P = 0.04). IL-10 is a potent inhibitor of LPS-stimulated GM-CSF production from healthy control alveolar macrophages. These studies are the first to demonstrate that circulating monocytes and alveolar macrophages from PAP patients are able to synthesize GM-CSF and respond to GM-CSF, suggesting no intrinsic abnormalities in GM-CSF signaling. In addition, these observations suggest that PAP in a subset of patients is the result of decreased availability of GM-CSF due to GM-CSF blocking activity and reduced GM-CSF production by IL-10.

References (27)

  • D.W. Golde et al.

    Defective lung macrophages in pulmonary alveolar proteinosis

    Ann. Intern. Med.

    (1976)
  • E.D. Thomas et al.

    Direct evidence for a bone marrow origin of the alveolar macrophage in man

    Science

    (1976)
  • R. Andreesen et al.

    Surface phenotype analysis of human monocyte to macrophage maturation

    J. Leukocyte Biol.

    (1990)
  • Cited by (67)

    • Pulmonary surfactant metabolism in the alveolar airspace: Biogenesis, extracellular conversions, recycling

      2017, Annals of Anatomy
      Citation Excerpt :

      Finally, beyond disorders in surfactant production, secretion or reuptake by type II pneumocytes, an impairment of surfactant clearance and catabolism by macrophages may also cause several forms of PAP. These may be due to GMCSF mutations or autoantibodies, or to a decrease in the number of alveolar macrophages or their function, secondary to other disorders (Kitamura et al., 1999; Thomassen et al., 2000; Carey and Trapnell, 2010). It is also important to consider the implication of the lipid transporters ABCG1 and ABCA1 in the alveolar accumulation of lipids and cholesterol at PAP patients (Malur et al., 2011; Gowdy and Fessler, 2013).

    • Alveolar macrophage activation in obese patients with obstructive sleep apnea

      2012, Surgery
      Citation Excerpt :

      Channels included nasal pressure transducers, snore channel, recordings of abdominal and chest movement using respiratory and inductive plethysmography, pulse oximetry, and heart rate monitoring (Easy III ambulatory PSG system, Cadwell). Alveolar macrophages were derived from BAL obtained by fiberoptic bronchoscopy performed for research as described previously.17 Briefly, bronchoscopy was performed in an ambulatory setting using conscious sedation.

    • Lentivirus-ABCG1 instillation reduces lipid accumulation and improves lung compliance in GM-CSF knock-out mice

      2011, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      In mice homozygous for a disrupted GM-CSF gene or for the common β-chain of the GM-CSF/IL-3/IL-5 receptor gene, an excess of pulmonary surfactant occurs which histologically resembles the human disease, pulmonary alveolar proteinosis (PAP) [18,31,36]. PAP however is characterized by the presence of neutralizing anti-GM-CSF autoantibodies that effectively block GM-CSF signaling pathways in surfactant homeostasis [22,38]. The result is that in both species, alveolar macrophages accumulate excess intracellular neutral lipids which are detectable by Oil Red O staining. [20,37].

    • Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia

      2010, Blood
      Citation Excerpt :

      Most patients had severe or disseminated human papillomavirus (HPV) infection, whereas several also had disseminated histoplasmosis, invasive aspergillosis, or cryptococcal meningitis. Pulmonary alveolar proteinosis (PAP), a condition resulting from abnormalities in pulmonary alveolar macrophage metabolism of granulocyte-macrophage colony-stimulating factor (GM-CSF) or surfactant,10-14 developed in 5 patients with long-standing disease. All affected persons demonstrated persistent and profound peripheral monocytopenia, B-cell and NK-cell lymphocytopenia, with variable T-cell lymphocytopenia.

    • Molecular Basis of Pulmonary Disease

      2009, Molecular Pathology: The Molecular Basis of Human Disease
    View all citing articles on Scopus
    View full text